Literature DB >> 24838857

Enhanced suppressor function of TIM-3+ FoxP3+ regulatory T cells.

Anne-Sophie Gautron1, Margarita Dominguez-Villar1, Marine de Marcken1, David A Hafler1.   

Abstract

T-cell immunoglobulin and mucin domain 3 (TIM-3) is an Ig-superfamily member expressed on IFN-γ-secreting Th1 and Tc1 cells and was identified as a negative regulator of immune tolerance. TIM-3 is expressed by a subset of activated CD4(+) T cells, and anti-CD3/anti-CD28 stimulation increases both the level of expression and the number of TIM-3(+) T cells. In mice, TIM-3 is constitutively expressed on natural regulatory T (Treg) cells and has been identified as a regulatory molecule of alloimmunity through its ability to modulate CD4(+) T-cell differentiation. Here, we examined TIM-3 expression on human Treg cells to determine its role in T-cell suppression. In contrast to mice, TIM-3 is not expressed on Treg cells ex vivo but is upregulated after activation. While TIM-3(+) Treg cells with increased gene expression of LAG3, CTLA4, and FOXP3 are highly efficient suppressors of effector T (Teff) cells, TIM-3(-) Treg cells poorly suppressed Th17 cells as compared with their suppression of Th1 cells; this decreased suppression ability was associated with decreased STAT-3 expression and phosphorylation and reduced gene expression of IL10, EBI3, GZMB, PRF1, IL1Rα, and CCR6. Thus, our results suggest that TIM-3 expression on Treg cells identifies a population highly effective in inhibiting pathogenic Th1- and Th17-cell responses.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  FoxP3; Regulatory T (Treg) cells; TIM-3; Th17

Mesh:

Substances:

Year:  2014        PMID: 24838857      PMCID: PMC4165702          DOI: 10.1002/eji.201344392

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  42 in total

1.  Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells.

Authors:  Thomas Duhen; Rebekka Duhen; Antonio Lanzavecchia; Federica Sallusto; Daniel J Campbell
Journal:  Blood       Date:  2012-03-21       Impact factor: 22.113

2.  Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs.

Authors:  Shipra Gupta; Thomas B Thornley; Wenda Gao; Rafael Larocca; Laurence A Turka; Vijay K Kuchroo; Terry B Strom
Journal:  J Clin Invest       Date:  2012-06-11       Impact factor: 14.808

3.  HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.

Authors:  Bahareh Vali; R Brad Jones; Ali Sakhdari; Prameet M Sheth; Kiera Clayton; Feng-Yun Yue; Gabor Gyenes; David Wong; Marina B Klein; Sahar Saeed; Erika Benko; Colin Kovacs; Rupert Kaul; Mario A Ostrowski
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

4.  Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease.

Authors:  Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo
Journal:  Nature       Date:  2002-01-31       Impact factor: 49.962

5.  Premature terminal exhaustion of Friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors.

Authors:  Shiki Takamura; Sachiyo Tsuji-Kawahara; Hideo Yagita; Hisaya Akiba; Mayumi Sakamoto; Tomomi Chikaishi; Maiko Kato; Masaaki Miyazawa
Journal:  J Immunol       Date:  2010-03-29       Impact factor: 5.422

6.  Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.

Authors:  Rachel H McMahan; Lucy Golden-Mason; Michael I Nishimura; Brian J McMahon; Michael Kemper; Todd M Allen; David R Gretch; Hugo R Rosen
Journal:  J Clin Invest       Date:  2010-11-15       Impact factor: 14.808

Review 7.  Emerging Tim-3 functions in antimicrobial and tumor immunity.

Authors:  Kaori Sakuishi; Pushpa Jayaraman; Samuel M Behar; Ana C Anderson; Vijay K Kuchroo
Journal:  Trends Immunol       Date:  2011-06-21       Impact factor: 16.687

Review 8.  Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases.

Authors:  Jane Hoyt Buckner
Journal:  Nat Rev Immunol       Date:  2010-12       Impact factor: 53.106

Review 9.  Human CD4+CD25+ regulatory T cells.

Authors:  Clare Baecher-Allan; Vissia Viglietta; David A Hafler
Journal:  Semin Immunol       Date:  2004-04       Impact factor: 11.130

10.  TIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progression.

Authors:  Xin Gao; Yibei Zhu; Gang Li; Haitao Huang; Guangbo Zhang; Fengming Wang; Jing Sun; Qianting Yang; Xueguang Zhang; Binfeng Lu
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

View more
  73 in total

Review 1.  Strategies for combining immunotherapy with radiation for anticancer therapy.

Authors:  Steven N Seyedin; Jonathan E Schoenhals; Dean A Lee; Maria A Cortez; Xiaohong Wang; Sharareh Niknam; Chad Tang; David S Hong; Aung Naing; Padmanee Sharma; James P Allison; Joe Y Chang; Daniel R Gomez; John V Heymach; Ritsuko U Komaki; Laurence J Cooper; James W Welsh
Journal:  Immunotherapy       Date:  2015-08-27       Impact factor: 4.196

Review 2.  Next generation immune-checkpoints for cancer therapy.

Authors:  Chiara Donini; Lorenzo D'Ambrosio; Giovanni Grignani; Massimo Aglietta; Dario Sangiolo
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

Review 4.  Role of Tim-3 in hepatitis B virus infection: An overview.

Authors:  Yuan Liu; Li-Fen Gao; Xiao-Hong Liang; Chun-Hong Ma
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

Review 5.  Immunological landscape and immunotherapy of hepatocellular carcinoma.

Authors:  Jesús Prieto; Ignacio Melero; Bruno Sangro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-10-20       Impact factor: 46.802

6.  Ovarian carcinoma-infiltrating regulatory T cells were more potent suppressors of CD8(+) T cell inflammation than their peripheral counterparts, a function dependent on TIM3 expression.

Authors:  Meimei Bu; Yizhen Shen; William L Seeger; Shizhi An; Rongqin Qi; Joanna A Sanderson; Yan Cai
Journal:  Tumour Biol       Date:  2015-10-19

7.  A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.

Authors:  Zachary T Freeman; Thomas R Nirschl; Daniel H Hovelson; Robert J Johnston; John J Engelhardt; Mark J Selby; Christina M Kochel; Ruth Y Lan; Jingyi Zhai; Ali Ghasemzadeh; Anuj Gupta; Alyza M Skaist; Sarah J Wheelan; Hui Jiang; Alexander T Pearson; Linda A Snyder; Alan J Korman; Scott A Tomlins; Srinivasan Yegnasubramanian; Charles G Drake
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 8.  Modulation of regulatory T cell function and stability by co-inhibitory receptors.

Authors:  Liliana E Lucca; Margarita Dominguez-Villar
Journal:  Nat Rev Immunol       Date:  2020-04-08       Impact factor: 53.106

Review 9.  Tim-3, Lag-3, and TIGIT.

Authors:  Nicole Joller; Vijay K Kuchroo
Journal:  Curr Top Microbiol Immunol       Date:  2017       Impact factor: 4.291

Review 10.  Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation.

Authors:  Ana C Anderson; Nicole Joller; Vijay K Kuchroo
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.